Safety and efficacy of New-Fill® (Polylactic acid) in the treatment of HIV-associated lipoatrophy of the face (HALF)

被引：0
|
作者：
Engelhard, P [1 ]
Knies, M [1 ]
机构：
[1] Apex S Beach, Miami Beach, FL USA
来源：
XIV INTERNATIONAL AIDS CONFERENCE: CLINICAL SCIENCES AND CARE | 2002年
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
Various techniques have been employed in an attempt to correct the cosmetic facial defects caused by HIV-Associated Lipoatrophy of the Face (HALF) (1). This study presents data regarding the short-term (6 month) efficacy and safety of New-Fill(R) (Polylactic Acid) in the treatment of HALF. Overall, treatment with New-Fill(R) results in significant improvement in subject self-reported lipoatrophy rating and good subject satisfaction with treatment outcome at 6 months.
引用
收藏
页码：365 / 367
页数：3
相关论文
共 50 条
  • [1] Safety and Efficacy of a Volumizing Hyaluronic Acid Filler for Treatment of HIV-Associated Facial Lipoatrophy
    Ho, Derek
    Jagdeo, Jared
    JAMA DERMATOLOGY, 2017, 153 (01) : 61 - 65
  • [2] Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy
    Burgess, CM
    Quiroga, RM
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (02) : 233 - 239
  • [3] Long-term efficacy and safety of polyalkylimide gel for the treatment of HIV-associated lipoatrophy
    Antoniou, Tony
    Raboud, Janet M.
    Kovacs, Colin
    Diong, Christina
    Brunetta, Jason
    Smith, Graham
    Halpenny, Roberta
    Beninger, Francis
    Loutfy, Mona R.
    AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2009, 21 (10): : 1247 - 1252
  • [4] Long-term safety and efficacy of eutrophill for treatment of HIV-associated facial lipoatrophy
    Carbonnel, E.
    Mole, B.
    Kazatchkine, M.
    Claudy, A.
    ANTIVIRAL THERAPY, 2006, 11 (07) : L60 - L60
  • [5] Polylactic acid implants (New-Fill)® to correct facial lipoatrophy in HIV-infected patients:: results of the open-label study VEGA
    Valantin, MA
    Aubron-Olivier, C
    Ghosn, J
    Laglenne, E
    Pauchard, M
    Schoen, H
    Bousquet, R
    Katz, P
    Costagliola, D
    Katlama, C
    AIDS, 2003, 17 (17) : 2471 - 2477
  • [6] Safety of poly-L-lactic acid (New-Fill®) in the treatment of facial lipoatrophy: a large observational study among HIV-positive patients
    Martin Duracinsky
    Pascale Leclercq
    Susan Herrmann
    Marie-Odile Christen
    Marc Dolivo
    Cécile Goujard
    Olivier Chassany
    BMC Infectious Diseases, 14
  • [7] Safety of poly-L-lactic acid (New-Fill®) in the treatment of facial lipoatrophy: a large observational study among HIV-positive patients
    Duracinsky, Martin
    Leclercq, Pascale
    Herrmann, Susan
    Christen, Marie-Odile
    Dolivo, Marc
    Goujard, Cecile
    Chassany, Olivier
    BMC INFECTIOUS DISEASES, 2014, 14
  • [8] Hyaluronic acid new formulation: Experience in HIV-associated facial lipoatrophy
    Bechara, Falk G.
    Gambichler, Thilo
    Brockmeyer, Norbert H.
    Sand, Michael
    Altmeyer, Peter
    Hoffmann, Klaus
    DERMATOLOGY, 2008, 217 (03) : 244 - 249
  • [9] Safety and efficacy of poly-L-lactic acid injections in persons with HIV-associated lipoatrophy: The US experience
    Mest, Douglas R.
    Humble, Gail
    DERMATOLOGIC SURGERY, 2006, 32 (11) : 1336 - 1345
  • [10] Safety and efficacy of intradermal poly-L-lactic acid (Sculptra™) injections in patients with HIV-associated facial lipoatrophy
    Mest, DR
    Humble, G
    ANTIVIRAL THERAPY, 2004, 9 (06) : L36 - L37
12345